Baxter International (NYSE:BAX) Lowered to “Hold” Rating by StockNews.com

StockNews.com downgraded shares of Baxter International (NYSE:BAXFree Report) from a buy rating to a hold rating in a research note released on Monday morning.

BAX has been the topic of a number of other reports. Wells Fargo & Company decreased their target price on Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 7th. JPMorgan Chase & Co. reduced their price objective on shares of Baxter International from $44.00 to $42.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Stifel Nicolaus cut their price target on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Monday. The Goldman Sachs Group raised their price objective on shares of Baxter International from $36.00 to $40.00 and gave the stock a “neutral” rating in a research note on Thursday, August 8th. Finally, Morgan Stanley lowered Baxter International from an “equal weight” rating to an “underweight” rating and reduced their target price for the company from $39.00 to $30.00 in a report on Monday, July 15th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $40.91.

Check Out Our Latest Analysis on BAX

Baxter International Trading Down 1.2 %

Shares of NYSE BAX opened at $34.22 on Monday. The stock’s 50 day simple moving average is $37.31 and its 200 day simple moving average is $36.01. The company has a current ratio of 1.40, a quick ratio of 0.91 and a debt-to-equity ratio of 1.35. The company has a market cap of $17.46 billion, a price-to-earnings ratio of 171.10, a price-to-earnings-growth ratio of 1.17 and a beta of 0.60. Baxter International has a 12-month low of $32.48 and a 12-month high of $44.01.

Baxter International (NYSE:BAXGet Free Report) last announced its earnings results on Friday, November 8th. The medical instruments supplier reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The firm had revenue of $3.85 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter in the previous year, the business earned $0.68 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities research analysts expect that Baxter International will post 2.93 EPS for the current year.

Baxter International Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 2nd. Shareholders of record on Friday, November 29th will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 1.99%. Baxter International’s dividend payout ratio (DPR) is currently 580.00%.

Hedge Funds Weigh In On Baxter International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. LSV Asset Management acquired a new position in shares of Baxter International during the 2nd quarter worth $140,296,000. Bank of New York Mellon Corp raised its holdings in shares of Baxter International by 73.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 6,772,533 shares of the medical instruments supplier’s stock valued at $226,541,000 after purchasing an additional 2,862,626 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new position in shares of Baxter International during the 2nd quarter valued at $67,263,000. Coho Partners Ltd. bought a new position in shares of Baxter International during the 3rd quarter valued at $57,229,000. Finally, Shapiro Capital Management LLC raised its holdings in shares of Baxter International by 19.7% during the 2nd quarter. Shapiro Capital Management LLC now owns 3,285,048 shares of the medical instruments supplier’s stock valued at $109,885,000 after purchasing an additional 541,575 shares in the last quarter. Institutional investors own 90.19% of the company’s stock.

Baxter International Company Profile

(Get Free Report)

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

Recommended Stories

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.